Compare ACADIA Pharmaceuticals Inc. (ACAD) vs New York Times Co (NYT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs New York Times Co — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while New York Times Co trades at $73.31 (market cap $11.93B). The key difference: New York Times Co is far larger — about 2.7× ACADIA Pharmaceuticals Inc.'s market cap, and New York Times Co pays a 1.25% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | NYT | |
|---|---|---|
Market Cap | $4.49B | $11.93B |
Sector | Health | Media |
52-Week High | $28.06 | $85.86 |
52-Week Low | $20.06 | $51.43 |
Enterprise Value | $3.69B | $11.33B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
The New York Times Company (NYT) trades at $73.72, showing modest daily movement. The stock exhibits a bullish technical trend with strong moving average signals. Fundamentally, the company demonstrates consistent revenue growth, expanding profit margins, and robust cash flow from operations. Recent quarterly earnings have consistently surpassed analyst expectations, reflecting operational strength. A dividend of $0.23 per share is scheduled for payment in July 2026.
The outlook for NYT is positive, supported by solid financial performance and a 'Buy' analyst consensus with a $78.00 price target, implying potential upside. Key opportunities include sustained digital subscription growth and margin expansion. Primary risks involve competitive pressures in the media landscape and broader economic sensitivity affecting advertising revenue. The stock presents a compelling case for investors seeking a stable, growing media company.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
